Search Results - gpc2

4 Results

Sort By:

Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma

Abstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed....

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Carol Thiele Galetto, Nan Li, Rosa Nguyen, Rosandra Kaplan

Keywords(s): CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma

Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov

Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers

Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dan Li

Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology